OmniAb (NASDAQ:OABI – Get Free Report) is one of 40 public companies in the “Commercial physical research” industry, but how does it compare to its peers? We will compare OmniAb to related businesses based on the strength of its profitability, institutional ownership, analyst recommendations, risk, dividends, earnings and valuation.
Profitability
This table compares OmniAb and its peers’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| OmniAb | N/A | -6.38% | -4.33% |
| OmniAb Competitors | -2,646.34% | -103.25% | -22.46% |
Analyst Ratings
This is a breakdown of recent ratings and price targets for OmniAb and its peers, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| OmniAb | 0 | 0 | 9 | 0 | 3.00 |
| OmniAb Competitors | 49 | 788 | 1321 | 30 | 2.61 |
Institutional and Insider Ownership
58.7% of OmniAb shares are owned by institutional investors. Comparatively, 52.3% of shares of all “Commercial physical research” companies are owned by institutional investors. 7.0% of OmniAb shares are owned by insiders. Comparatively, 14.9% of shares of all “Commercial physical research” companies are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Earnings & Valuation
This table compares OmniAb and its peers top-line revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| OmniAb | $59.08 million | -$22.33 million | -23.65 |
| OmniAb Competitors | $1.69 billion | $77.14 million | 3.38 |
OmniAb’s peers have higher revenue and earnings than OmniAb. OmniAb is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Volatility and Risk
OmniAb has a beta of -0.55, meaning that its stock price is 155% less volatile than the S&P 500. Comparatively, OmniAb’s peers have a beta of 5.48, meaning that their average stock price is 448% more volatile than the S&P 500.
Summary
OmniAb beats its peers on 7 of the 13 factors compared.
OmniAb Company Profile
OmniAb, Inc., a biotechnology company, engages in the provision of therapeutic antibody discovery technologies in the United States. The company's discovery platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company's OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications though a common light chain approach, and OmniTau, which features unique structural attributes of cow antibodies for complex targets. The company was founded in 2012 and is headquartered in Emeryville, California.
Receive News & Ratings for OmniAb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OmniAb and related companies with MarketBeat.com's FREE daily email newsletter.
